Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-05 10:29 am Unchanged | 2026-01-23 | 13D | Corvus Pharmaceuticals, Inc. CRVS | Adams Street Partners, LLC | 3,275,616 3.900% | 0 (Unchanged) | Filing History |
| 2026-01-30 1:26 pm Purchase | 2025-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | The Vanguard Group | 3,873,482 5.180% | 3,873,482 (New Position) | Filing History |
| 2026-01-27 8:38 pm Sale | 2026-01-23 | 13D | Corvus Pharmaceuticals, Inc. CRVS | ORBIMED ADVISORS LLC | 8,609,091 10.300% | -1,176,332 (-12.02%) | Filing History |
| 2025-10-17 6:40 pm Purchase | 2025-09-30 | 13G | Corvus Pharmaceuticals, Inc. CRVS | BlackRock Inc. BLK | 4,015,510 5.400% | 4,015,510 (New Position) | Filing History |
| 2025-08-14 1:32 pm Sale | 2025-06-30 | 13G | Corvus Pharmaceuticals, Inc. CRVS | Samlyn Capital, LLC | 0 0.000% | -4,065,935 (Position Closed) | Filing History |
| 2025-05-15 3:34 pm Sale | 2025-03-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | Samlyn Capital, LLC | 4,065,935 6.000% | -2,601,170 (-39.01%) | Filing History |
| 2025-05-14 8:49 pm Unchanged | 2025-05-12 | 13D | Corvus Pharmaceuticals, Inc. CRVS | ORBIMED ADVISORS LLC | 9,785,423 12.200% | 0 (Unchanged) | Filing History |
| 2025-05-01 9:20 pm Purchase | 2025-04-29 | 13D | Corvus Pharmaceuticals, Inc. CRVS | ORBIMED ADVISORS LLC | 9,785,423 13.800% | 2,841,769 (+40.93%) | Filing History |
| 2025-02-14 1:53 pm Purchase | 2024-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | Samlyn Capital, LLC | 6,667,105 9.800% | 403,347 (+6.44%) | Filing History |
| 2025-02-13 4:30 pm Purchase | 2024-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | MILLER RICHARD A MD | 5,220,368 7.700% | 1,536,358 (+41.70%) | Filing History |
| 2024-08-01 9:18 pm Sale | 2024-08-01 | 13G | Corvus Pharmaceuticals, Inc. CRVS | Samlyn Capital, LLC | 6,263,758 9.990% | -4,226 (-0.07%) | Filing History |
| 2024-05-13 4:52 pm Purchase | 2024-05-01 | 13G | Corvus Pharmaceuticals, Inc. CRVS | Samlyn Capital, LLC | 6,267,984 9.990% | 3,771,725 (+151.10%) | Filing History |
| 2024-05-09 5:29 pm Purchase | 2024-05-02 | 13G | Corvus Pharmaceuticals, Inc. CRVS | Point72 Asset Management, L.P. | 17,050,384 9.900% | 17,050,384 (New Position) | Filing History |
| 2024-05-08 7:55 pm Unchanged | 2024-05-06 | 13D | Corvus Pharmaceuticals, Inc. CRVS | ORBIMED ADVISORS LLC | 6,943,654 11.100% | 0 (Unchanged) | Filing History |
| 2024-02-14 1:31 pm Purchase | 2023-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | Samlyn Capital, LLC | 2,496,259 5.100% | 2,496,259 (New Position) | Filing History |
| 2024-02-13 6:27 pm Purchase | 2023-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | MILLER RICHARD A MD | 3,684,010 7.190% | 578,889 (+18.64%) | Filing History |
| 2023-02-14 4:00 pm Sale | 2022-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | TANG CAPITAL PARTNERS LP | 0 0.000% | -3,101,709 (Position Closed) | Filing History |
| 2023-02-13 12:01 pm Purchase | 2022-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | CHI Advisors LLC | 2,384,402 5.120% | 2,384,402 (New Position) | Filing History |
| 2023-02-10 4:00 pm Purchase | 2022-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | MILLER RICHARD A MD | 3,105,121 6.450% | 497,973 (+19.10%) | Filing History |
| 2023-01-30 4:17 pm Sale | 2022-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | Integrated Core Strategies (US) LLC | 1,899,516 4.100% | -1,020,543 (-34.95%) | Filing History |